Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study

Table 3 Treatment withdrawal and seizure freedom rates (Kaplan-Meier estimates) for sodium valproate and carbamazepine strata (intent-to-treat population)^a

Sodium valproate stratum		LEV	VPA-ER
		All seizure types n = 48	All seizure types n = 52
		Generalized seizures only n = 14	Generalized seizures only n = 22
Treatment withdrawal rate, % (95 % CI)
6 months	All seizure types	4.2 (1.1–15.7)	19.2 (10.8–32.8)
6 months	Generalized seizures only	7.1 (1.0–40.9)	18.2 (7.2–41.5)
12 months	All seizure types	10.4 (4.5–23.2)	23.1 (13.8–37.0)
12 months	Generalized seizures only	14.3 (3.8–46.1)	22.7 (10.2–46.3)
Seizure freedom rate, % (95 % CI)
6 months	All seizure types	70.4 (55.1–81.3)	63.4 (47.8–75.4)
6 months	Generalized seizures only	69.6 (37.8–87.4)	63.3 (38.1–80.6)
12 months	All seizure types	66.0 (50.5–77.6)	59.0 (43.5–71.6)
12 months	Generalized seizures only	–	52.8 (28.9–72.0)
Carbamazepine stratum		LEV	CBZ-CR
		All seizure types n = 104	All seizure types n = 103
		Focal seizures only n = 93	Focal seizures only n = 94
Treatment withdrawal rate, % (95 % CI)
6 months	All seizure types	19.2 (12.9–28.2)	41.8 (32.9–51.9)
6 months	Focal seizures only	18.3 (11.8–27.8)	40.4 (31.3–51.1)
12 months	All seizure types	25.0 (17.8–34.5)	46.6 (37.6–56.7)
12 months	Focal seizures only	24.7 (17.2–34.8)	45.8 (36.4–56.4)
Seizure freedom rate, % (95 % CI)
6 months	All seizure types	63.3 (52.6–72.1)	63.2 (51.4–72.8)
6 months	Focal seizures only	59.3 (48.0–68.9)	63.1 (51.0–73.1)
12 months	All seizure types	59.8 (49.1–69.0)	59.8 (47.7–69.9)
12 months	Focal seizures only	55.5 (44.2–65.4)	61.3 (49.0–71.5)

Abbreviations: CBZ-CR controlled-release carbamazepine, CI confidence interval, LEV levetiracetam, VPA-ER extended-release sodium valproate
^aFor the sodium valproate stratum, data are presented for all patients (intent-to-treat population excluding unclassified seizure types) and those with generalized seizures only (intent-to-treat population excluding unclassified, unknown and mixed seizure types). For the carbamazepine stratum, data are presented for all patients (intent-to-treat population excluding unclassified seizure types) and those with focal seizures only (intent-to-treat population excluding unclassified, unknown and mixed seizure types)

ISSN: 1471-2377